Sign in
4

Changes in Ownership

HALOZYME THERAPEUTICS, INC. Filed Acc 0001528185-25-000004

PRESIDENT AND CEO sold 60,000 shares at an average $71.86 ($4,311,745)

  • PRESIDENT AND CEO acquired 60,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Torley Helen · PRESIDENT AND CEO

Table I: Non-derivative

14 lines
Date Transaction Shares Price Value Owned after D/I
2025-10-01 Exercise or conversion : show line 1 in the form 10b5-1 +20,000 $8.11 $162,200 753,719 D
2025-10-01 Sale : show line 2 in the form 10b5-1 −11,705 $75.11 $879,151 742,014 D
2025-10-01 Sale : show line 3 in the form 10b5-1 −8,295 $75.69 $627,873 733,719 D
2025-10-02 Exercise or conversion : show line 4 in the form 10b5-1 +20,000 $8.11 $162,200 753,719 D
2025-10-02 Sale : show line 5 in the form 10b5-1 −6,600 $70.51 $465,359 747,119 D
2025-10-02 Sale : show line 6 in the form 10b5-1 −10,200 $71.28 $727,036 736,919 D
2025-10-02 Sale : show line 7 in the form 10b5-1 −2,400 $72.07 $172,956 734,519 D
2025-10-02 Sale : show line 8 in the form 10b5-1 −700 $73.24 $51,265 733,819 D
Open-market sales · 60,000 sh · avg $71.86 · $4,311,745

Table II: Derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2025-10-01 Exercise or conversion : show line 15 in the form 10b5-1 Option to Purchase Common Stock −20,000 $8.11 $162,200 116,569 D
2025-10-02 Exercise or conversion : show line 16 in the form 10b5-1 Option to Purchase Common Stock −20,000 $8.11 $162,200 96,569 D
2025-10-03 Exercise or conversion : show line 17 in the form 10b5-1 Option to Purchase Common Stock −20,000 $8.11 $162,200 76,569 D
Loading xslF345X05/form4-10032025_091059.xml…